Congress mandates pediatric cancer gets population-share of all federal cancer research funding
H.R. 6054 — Fairness to Kids with Cancer Act of 2025 · Filed by Brian Fitzpatrick (R-PA) · 6 cosponsors · Introduced Nov 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to dedicate a percentage of all cancer research funding to pediatric cancer research equal to the percentage of the U.S. population under age 18. Starting in fiscal year 2026, if children make up (for example) 22% of the population, then 22% of federal cancer research dollars must go to pediatric cancer research. The bill gives the President responsibility for ensuring this allocation happens.
Why we flagged it
The bill's sole operative mechanism is a mandatory reallocation of existing federal cancer research appropriations. It does not create new funding; it redistributes current dollars based on demographic proportion. This is a straightforward funding-priority directive, not a new program or regulatory change.
What the text implies
- The bill does not specify which agencies (NIH, NCI, etc.) must implement the reallocation or how they will adjust existing grants and commitments mid-stream.
- Using population proportion as the metric means pediatric cancer research funding will fluctuate annually with Census Bureau population estimates, creating budget uncertainty.
- The bill does not address whether the reallocation applies to all federal cancer research (including DoD, VA, NSF) or only NIH/NCI funding, potentially creating implementation ambiguity.
- Adult cancer research funding will decline in absolute or relative terms, which may affect ongoing trials, researcher retention, and institutional capacity in adult oncology.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Children with cancer and their families gain increased research funding and potential therapeutic advances. However, adult cancer patients—who account for the vast majority of cancer cases and deaths—face reduced research funding for their conditions, creating a real trade-off between two vulnerable populations rather than a pure public benefit.
Who stands to gain
- pediatric cancer research institutions and hospitals
- pediatric oncology researchers and academic medical centers
- pharmaceutical and biotech companies developing pediatric cancer therapeutics
Named in the bill
President, Bureau of the Census, National Institutes of Health (NIH), National Cancer Institute (NCI), Federal cancer research programs
Where it stands
6 cosponsors: 4 Democrats, 2 Republicans.
- Nov 17, 2025 — Introduced · Congress.gov: “Introduced in House”
- Nov 17, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (870 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress mandates pediatric cancer gets population-share of all federal cancer research funding” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6054 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.